Evidence map›Paper›PMID 41037149›Full record

ArticleJournal of cardiovascular translational research2025

FGF21 Blunts Cardiac Ischemia/Reperfusion Injury by Promoting Autophagic Flux Via Stat1/Irgm1 Pathway.

Tao Tu, Zuodong Ning, Yuhu He, Yingxu Ma, Yichao Xiao, Zhaowei Zhu, Liang Tang, Xuping Li, Hui Yang, Mingxian Chen and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cardiovascular translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tao Tu *Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Renmin Road 139, Changsha, Hunan, 410011, PR China.ORCID 0000-0001-5508-4369
Zuodong Ning *Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Renmin Road 139, Changsha, Hunan, 410011, PR China.
Yuhu HeDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Renmin Road 139, Changsha, Hunan, 410011, PR China.
Yingxu MaDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Renmin Road 139, Changsha, Hunan, 410011, PR China.
Yichao XiaoDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Renmin Road 139, Changsha, Hunan, 410011, PR China.
Zhaowei ZhuDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Renmin Road 139, Changsha, Hunan, 410011, PR China.
Liang TangDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Renmin Road 139, Changsha, Hunan, 410011, PR China.
Xuping LiDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Renmin Road 139, Changsha, Hunan, 410011, PR China.
Hui YangDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Renmin Road 139, Changsha, Hunan, 410011, PR China.
Mingxian ChenDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Renmin Road 139, Changsha, Hunan, 410011, PR China.
Shi TaiDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Renmin Road 139, Changsha, Hunan, 410011, PR China.
Qiming LiuDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Renmin Road 139, Changsha, Hunan, 410011, PR China. qimingliu@csu.edu.cn.
Shenghua ZhouDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Renmin Road 139, Changsha, Hunan, 410011, PR China. zhoushenghua@csu.edu.cn.ORCID 0000-0002-2830-6787

Funding

National Natural Science Foundation of China 81600273National Natural Science Foundation of China 81870258National Natural Science Foundation of China 82070356National Natural Science Foundation of China 82150006National Natural Science Foundation of China 82270337
6 · The paper itself

Abstract

This study aimed to investigate the underlying mechanisms of Fibroblast Growth Factor 21 (FGF21) in myocardial ischemia/reperfusion (I/R) injury. First, FGF21 was upregulated in the serum of patients with myocardial I/R injury as well as in I/R hearts of mice and hypoxia/reoxygenation (H/R) neonatal rat cardiomyocytes (NRCMs). While FGF21 knockout exacerbated such injury, which was mitigated by rhFGF21. Bioinformatics analysis identified immunity-related GTPase M1 (Irgm1) as a key autophagy-related gene downregulated in ventricular tissue of FGF21

Indexed as

AutophagyFibroblast Growth FactorsMyocardial Reperfusion InjuryMyocytes, CardiacSTAT1 Transcription FactorAnimalsCells, CulturedDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLMice, KnockoutRatsSignal TransductionFGF21 protein, humanfibroblast growth factor 21Fibroblast Growth FactorsStat1 protein, mouseSTAT1 Transcription FactorAutophagic fluxAutophagyFibroblast growth factor 21Irgm1Myocardial ischemia/reperfusion injury

Identifiers

PMID41037149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.